Metformin in PMP from appendiceal mucinous neoplasms

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-arm, open-label, Phase 2 pilot study to determine if metformin can be feasibly given to patients with PMP secondary to AMNs. Treatment continues for up to 18 months or until intolerance. The primary goal is to assess feasibility of metformin therapy in this patient population, with eligibility limited to adults with recurrent or unresectable PMP who have had prior CRS/HIPEC or are not planned for such procedures. No comparison group is included; outcomes focus on tolerability and practical administration. The study is conducted at UC Irvine's Chao Family Comprehensive Cancer Center under the lead sponsorship of UC Irvine.

Why it matters

Who can join: the full rules

Key Inclusion Criteria (complete details available in protocol):

* Patients with clinical diagnosis of pseudomyxoma peritonei (PMP) secondary to presumed appendiceal mucinous neoplasms (AMNs) with recurrent/refractory disease s/p cytoreductive surgery(CRS)/hyperthermic intraperitoneal chemotherapy (HIPEC), unresectable disease, or without planned CRS/HIPEC
* Age ≥18 years
* ECOG performance status ≤2

Key Exclusion Criteria (complete details available in protocol):

* Patients with a clinical diagnosis of PMP secondary to presumed AMNs with resectable disease who are planned to undergo CRS/HIPEC
* Patients currently taking metformin for another medical indication
* Patients with a prior adverse event to administration of metformin

Where it's running

• Chao Family Comprehensive Cancer Center, University of California, Irvine
  Orange, California, United States Recruiting

Study contacts

• Principal investigator: Oliver Eng, MD — Chao Family Comprehensive Cancer Center
• Study coordinator: Chao Family Comprehensive Cancer Center University of California, Irvine
• Email: ucstudy@uci.edu
• Phone: 1-877-827-8839

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Appendix Cancer and PMP Patient Registry and Natural History Study

  This global, patient-powered registry tests how appendix cancer and pseudomyxoma peritonei progress over time by collecting real-world data from patients and caregivers.

  Recruiting Appendix Cancer Pseudomyxoma Peritonei Research Foundation · Springfield, Pennsylvania · NCT07769346

• Pseudovax: a vaccine for people with pseudomyxoma peritonei

  This trial will test whether the Pseudovax peptide vaccine with GM‑CSF plus the PD‑1 drug tislelizumab can boost anti‑tumor immunity in adults with GNAS‑mutated pseudomyxoma peritonei.

  Recruiting Early Phase 1 Oslo University Hospital · Oslo, Oslo · NCT07341360

• One versus three HIPEC cycles after cytoreductive surgery for pseudomyxoma peritonei

  This study will see if giving three HIPEC sessions instead of one after cytoreductive surgery helps people with pseudomyxoma peritonei live longer, delay disease progression, and keep a better quality of life.

  Recruiting Beijing Tsinghua Chang Gung Hospital · Beijing, Changping · NCT07328737

• Neoadjuvant treatment for patients with advanced Pseudomyxoma peritonei

  This study is testing a new combination of medications to see if it can help patients with advanced Pseudomyxoma peritonei have better surgery results.

  Recruiting Phase 2 Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan · NCT06800391

• Comparing low-dose and high-dose chemotherapy for treating Pseudomyxoma Peritonei

  This study is testing if a lower dose of chemotherapy given for a shorter time can work just as well as a higher dose for treating Pseudomyxoma Peritonei.

  Recruiting Phase 3 University of Southampton · Basingstoke, Hampshire · NCT06513065

• Investigating the genetics of appendix cancer

  This study is trying to find out how genetics might play a role in appendix cancer by following adults with the disease for up to six years.

  Recruiting Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT05734430

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.